Critical limb ischemia – Pipeline Review, 2019

Critical limb ischemia sometimes referred as chronic limb threatening ischemia is a critical disorder in which inadequate blood and oxygen flow to any particular part of the body causes tissue damage leading to limb loss. This condition is predominately caused by the blockage and narrowing of the blood vessels of the specific body part that includes, brain, limb, heart among others. Critical limb ischemia is regarded as an advanced stage of peripheral artery disease (PAD). According to the researchers from the University of Michigan, an estimated 0.23% of the U.S population suffer from critical limb ischemia. Critical limb ischemia puts the patient at a higher risk of limb amputation.

Current treatment of critical limb ischemia depends on the type, location, and severity of the disease. The treatment option focuses on increasing the blood supply to the affected body part. Bypass surgeries that use surgical revascularization have been the gold standard for the treatment of chronic limb ischemia. Medications that control high blood pressure and cholesterol are prescribed to prevent the progression of the disease.

Various pharmaceutical industries and government organizations are cumulatively developing devices and therapeutic drugs to treat critical limb ischemia. For instance, REX-001, a drug developed by Rexgenero Ltd is under Phase III clinical trial.

At present around 67% of the pipeline candidates for critical limb ischemia are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Critical limb ischemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for critical limb ischemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Critical limb ischemia.

The report on ‘Critical limb ischemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Critical limb ischemia


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Critical limb ischemia


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary